Protecting Renal Function in Chronic Kidney Disease Patients with Isolated Nighttime Hypertension

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

NOT_YET_RECRUITING

Clinical Phase

NA

Total Enrollment

200 participants

Study Classification

INTERVENTIONAL

Study Start Date

2025-01-30

Study Completion Date

2028-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Hypertension guidelines recommend the application of ambulatory blood pressure monitoring in the diagnosis and treatment of patients with hypertension. Subtypes of hypertension such as nocturnal hypertension can be found through ambulatory blood pressure monitoring. Previous studies have reported that the prevalence of nocturnal hypertension, even isolated nocturnal hypertension, is higher in patients with chronic kidney disease, and it is associated with adverse events such as cardiovascular events and progression of renal dysfunction. However, the benefit of controlling nocturnal hypertension in patients with chronic kidney disease is unclear. In this study, a total of 200 patients with chronic kidney disease and isolated nocturnal hypertension will be enrolled. Patients will be randomly divided into two treatment groups: the active antihypertensive treatment group and the placebo treatment group (1:1). The antihypertensive treatment group will be treated with arotinolol or amlodipine and clonidine to control nocturnal blood pressure, while the control group will be treated with the corresponding placebos. Randomized patients will be followed up for 2 years to evaluate the effect of controlling isolated nocturnal hypertension on the progression of chronic kidney disease in terms of EPI-estimated glomerular filtration rate (eGFR) decline and change in proteinuria.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Indapamide Versus Hydrochlorothiazide in Elderly Hypertensive Patients With Renal Insufficiency

NCT01172431

Hypertension Renal Insufficiency

COMPLETED PHASE4

Effect of Arotinolol Hydrochloride on Cardiovascular Events in Hypertensive Haemodialysis Patients

NCT01351636

Chronic Kidney Disease

COMPLETED PHASE4

A New Application of Amiloride in the Treatment of Patient With Chronic Kidney Disease In Reducing Urinary PROtein

NCT03170336

Chronic Kidney Diseases

COMPLETED PHASE4

The Role of Isolated Nocturnal Hypertension Pattern in Nondialysis CKD

NCT03604003

Chronic Kidney Disease

UNKNOWN NA

Hypertension in Hemodialysis Patients (Aim 3)

NCT00582114

Hemodialysis Hypertension Left Ventricular Hypertrophy

TERMINATED PHASE3

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Chronic Kidney Disease(CKD) Nocturnal Hypertension

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

QUADRUPLE

Participants Caregivers Investigators Outcome Assessors

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Anti-hypertensive treatment group

The patients will be treated with Arotinolol and/or Amlodipine and/or Clonidine.

Group Type EXPERIMENTAL

Antihypertensive treatment with Arotinolol or Amlodipine or Clonidine

Intervention Type DRUG

Participants will receive Almar 10 mg orally once daily between 8:00 PM and midnight. At the subsequent visit, if nocturnal blood pressure remains above the target of \<120/70 mmHg, Amlodipine Besylate will be added at a dose of 2.5 mg to 5 mg orally once daily. Should nocturnal blood pressure still not achieve the target at the following visit, Clonidine Hydrochloride 75 µg will be added to the regimen. The target for nocturnal blood pressure control is set at \<120/70 mmHg. For participants whose clinic blood pressure exceeds 140/90 mmHg, an unscheduled visit will be arranged within one month. If elevated clinic blood pressure persists during this visit, a 24-hour Ambulatory Blood Pressure Monitoring (ABPM) will be conducted. If the ABPM results indicate daytime blood pressure ≥135/85 mmHg, open-label add-on antihypertensive therapy will be initiated, prioritizing the use of antihypertensive medications outside of the study drugs to achieve blood pressure control.

Control group

Placebo was used in the control group.

Group Type PLACEBO_COMPARATOR

Placebo-controlled group

Intervention Type DRUG

Participants are treated with corresponding placebo

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Antihypertensive treatment with Arotinolol or Amlodipine or Clonidine

Participants will receive Almar 10 mg orally once daily between 8:00 PM and midnight. At the subsequent visit, if nocturnal blood pressure remains above the target of \<120/70 mmHg, Amlodipine Besylate will be added at a dose of 2.5 mg to 5 mg orally once daily. Should nocturnal blood pressure still not achieve the target at the following visit, Clonidine Hydrochloride 75 µg will be added to the regimen. The target for nocturnal blood pressure control is set at \<120/70 mmHg. For participants whose clinic blood pressure exceeds 140/90 mmHg, an unscheduled visit will be arranged within one month. If elevated clinic blood pressure persists during this visit, a 24-hour Ambulatory Blood Pressure Monitoring (ABPM) will be conducted. If the ABPM results indicate daytime blood pressure ≥135/85 mmHg, open-label add-on antihypertensive therapy will be initiated, prioritizing the use of antihypertensive medications outside of the study drugs to achieve blood pressure control.

Intervention Type DRUG

Placebo-controlled group

Participants are treated with corresponding placebo

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Participants must be 18 years of age or older. All genders are eligible;
* Confirmed diagnosis of Chronic Kidney Disease (CKD) according to KDIGO. guidelines;
* UACR \< 30 mg/g (3.4 mg/mmol) and eGFR between 20-44 mL/min/1.73 m²; or UACR between 30-300 mg/g (3.4-33.9 mg/mmol) and eGFR between 20-59 mL/min/1.73 m²; or UACR between 300-5000 mg/g (33.9-565 mg/mmol) and eGFR \> 20 mL/min/1.73 m² (CKD-EPI equation).
* Office blood pressure measurements below 140/90 mmHg at both screening visits;
* Daytime ambulatory blood pressure \< 135/85 mmHg and nighttime systolic blood pressure ≥ 120 mmHg or diastolic blood pressure ≥ 70 mmHg;
* No use of corticosteroids, immunosuppressants, or biologic agents for at least one month prior to enrollment;

Exclusion Criteria

* Presence of acute kidney injury or acute renal failure;
* History of kidney transplantation;
* Presence of severe arrhythmias, including severe atrial fibrillation, atrioventricular (AV) block, sinoatrial (SA) block, sinus bradycardia, malignant AV node reentrant tachycardia syndrome;
* Secondary hypertension related to suspected or confirmed renal artery stenosis or adrenal gland disorders;
* Poor glycemic control (HbA1c \> 12%);
* Orthostatic hypotension (a decrease in blood pressure of \>20/10 mmHg within 3 minutes of standing from a sitting position);
* Women who are pregnant or breastfeeding at the time of enrollment, or not employing contraception of reproductive age;
* NYHA (New York Heart Association) Class III-IV congestive heart failure at the time of enrollment;
* History of myocardial infarction, unstable angina, acute heart failure, stroke, transient ischemic attack (TIA), or cerebral hemorrhage within the 12 weeks prior to enrollment;
* Underwent coronary revascularization (Percutaneous Coronary Intervention \[PCI\] or Coronary Artery Bypass Grafting \[CABG\]), or valve repair/replacement within the 12 weeks prior to enrollment, or planned to undergo any of the aforementioned surgical procedures after randomization;
* Any other serious diseases outside the renal and cardiovascular domains, including but not limited to malignancies, with an expected survival of less than 2 years based on the investigator's clinical judgment;
* Presence of active malignancy requiring pharmacological treatment;
* AST (Aspartate Aminotransferase) or ALT (Alanine Aminotransferase) levels \>3 times the upper limit of normal (ULN);
* Total bilirubin \>2 times ULN. Patients with Gilbert's syndrome who exhibit isolated bilirubin elevation do not need to be excluded;

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No